Aktiviertes Protein C im septischen Schock – contra

aktiviertes Protein C - Drotrecogin alfa - Sepsis - septischer Schock

aktivated protein C - drotrecogin alfa - sepsis - septic shock

Literatur

• 1 Angus D C. et al. PROWESS Investigators . The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.  Crit Care Med. 2004;  32 2199-2206
• 2 Bernard G R. et al . Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group..  N Engl J Med. 2001;  344 699-709
• 3 Brunkhorst F M. et al, German Sepsis Competence Network (SepNet) . Practice and perception.  Crit Care Med. 2008;  36 2719-2725
• 4 Eichacker P Q, Natanson C. Increasing evidence that the risks of rhAPC may outweigh its benefits.  Intensive Care Med. 2007;  33 396-399
• 5 Gao F. et al . The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis.  Crit Care. 2005;  9 R764-R770
• 6 Martí-Carvajal A, Salanti G, Cardona A F. Human recombinant activated protein C for severe sepsis.  Cochrane Database Syst Rev. 2007 CD004388; 
• 7 Poeze M. et al . An international sepsis survey: a study of doctors’ knowledge and perception about sepsis.  Crit Care. 2004;  8 R409-R413